000			01321nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aAdvances in DNA Vaccines
546			_aEnglish[eng]
650			_aalphaviruses||layered RNA/DNA vectors||DNA vaccines||RNA replicons||recombinant particles||tumor regression||protection against tumor challenges and infectious agents||ebola virus disease||artificial T-cell antigens||DNA vaccine constructs||computer design||gene expression||immunogenicity||DNA vaccine||mRNA vaccine||plasmid DNA||in vitro transcribed mRNA||immune responses||formulations||Cytolytic T Lymphocytes||antibodies||innate immunity||adjuvants||vaccine delivery||plasmid||cytolytic||perforin||bicistronic||HCV||HIV||IL-36||adjuvant||DNA||Zika||Epstein-Barr virus||latent proteins||LMP2||EBNA1||LMP1||HIV-1||enhancer element||circovirus||influenza||immunization||intranasal||lipid||flagellin||BCG||vaccine||rBCG||HTI||T-cell||AIDS||clinical trial||therapeutic vaccine||hepatitis C virus (HCV)||mesenchymal stem cells (MSC)||modified MSC||DNA immunization||nonstructural HCV proteins||immune response||HCV vaccine||myeloid derived suppressor cells (MDSCs)||n/a
700			_aIsaguliants, Maria||Ljungberg, Karl
856			_uhttps://mdpi.com/books/pdfview/book/4268
942			_cEB
999			_c27110 _d27110